Company name
2022Founder
Jason Ehrlich leads Ollin Biosciences, which develops therapies for vision-threatening eye diseases, including retinal conditions and thyroid eye disease. He previously served as chief medical officer and chief development officer at Kodiak Sciences and held ophthalmology leadership roles at Genentech, where he helped advance treatments for eye disease. He earned an MD and PhD from Stanford University School of Medicine.
Chief Executive Officer
CEO
Chief Medical Officer and Chief Development Officer
Bachelor's studies in biology
Cosign details are not available yet.
More profile details are not available yet.